Allergy Therapeutics plc
("Allergy Therapeutics" or the "Group")
Result of Annual General Meeting
7 February 2023 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces that all resolutions proposed at the 2022 Annual General Meeting ("AGM") held today were duly passed by shareholders on a show of hands.
Resolutions 1 to 10 (inclusive) were proposed as ordinary resolutions and resolution 11 was proposed as a special resolution. The results of the proxy votes received ahead of the meeting are outlined in the table below.
|
Resolution |
For: |
%age |
Against: |
%age |
Total Votes Cast |
% of ISC |
Withheld |
|
1. To re-elect Manual Llobet as a Director |
220,438,209 |
99.55 |
438,504 |
0.20 |
220,876,713 |
32.52 |
112,037 |
|
To re-elect Cheryl MacDiarmid as a Director |
220,433,972 |
99.55 |
448,778 |
0.20 |
220,882,750 |
32.53 |
106,000 |
|
3. To re-elect Anthony Parker as a Director |
218,552,445 |
98.70 |
2,324,268 |
1.05 |
220,876,713 |
32.52 |
112,037 |
|
4. To re-elect Zheqing (Simon) Shen as a Director |
218,556,682 |
98.70 |
2,326,068 |
1.05 |
220,882,750 |
32.53 |
106,000 |
|
5. To re-elect Mary Tavener as a Director |
220,433,972 |
99.55 |
442,741 |
0.20 |
220,876,713 |
32.52 |
112,037 |
|
6. To re-elect Tunde Otulana as a Director |
220,433,972 |
99.55 |
442,741 |
0.20 |
220,876,713 |
32.43 |
112,037 |
|
7. To re-elect Peter Jensen as a Director |
217,599,392 |
98.55 |
2,641,372 |
1.20 |
220,240,764 |
32.43 |
747,986 |
|
8. To re-appoint BDO LLP as auditors of the Company |
218,640,401 |
99.63 |
235,796 |
0.11 |
218,876,197 |
32.23 |
2,112,553 |
|
9. To authorise the Directors to agree the Auditors remuneration |
217,956,401 |
99.31 |
938,759 |
0.43 |
218,895,160 |
32.23 |
2,093,590 |
|
10. To authorise the Directors to allot the unissued share capital up to a specific amount (s.551) |
220,517,191 |
99.58 |
366,559 |
0.17 |
220,883,750 |
32.53 |
105,000 |
|
11. Special Resolution: To adopt the Articles of Association
|
220,515,891 |
99.60 |
336,822 |
0.15 |
220,852,713 |
32.52 |
136,037 |
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0)1903 845 820
Manuel Llobet, Chief Executive Officer
Martin Hopcroft, Interim Chief Financial Officer
Panmure Gordon (Nominated Adviser and Broker)
+44 (0)20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
Rupert Dearden, Corporate Broking
Consilium Strategic Communications
+44 (0)20 3709 5700
Mary-Jane Elliott / David Daley / Davide Salvi
allergytherapeutics@consilium-comms.com
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. For more information, please see www.allergytherapeutics.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
